Looking at the Director Review (DR) decisions so far in 2024, preliminary observations show that the landscape around the DR process appears to be shifting from sua-sponte focused DRs to party-initiated DRs.
Prior to the Supreme Court's 2021 decision in United States v. Arthrex, Inc., while there were some mechanisms for review of decisions by Patent Trial and Appeal Board (PTAB) panels, Director Review (DR) as a standalone review mechanism was essentially non-existent.
Collection
[
|
...
]